Cargando…

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials

SIMPLE SUMMARY: Breast cancer is a heterogeneous disease, which encompasses several subgroups of entities widely varying by clinical-pathological features. Triple negative breast cancer is characterized by a particularly aggressive biological behavior. The administration of chemotherapy has long rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marinelli, Daniele, Mazzotta, Marco, Pizzuti, Laura, Krasniqi, Eriseld, Gamucci, Teresa, Natoli, Clara, Grassadonia, Antonino, Tinari, Nicola, Tomao, Silverio, Sperduti, Isabella, Sanguineti, Giuseppe, Botticelli, Andrea, Fabbri, Agnese, Botti, Claudio, Ciliberto, Gennaro, Barba, Maddalena, Vici, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565914/ https://www.ncbi.nlm.nih.gov/pubmed/32899209 http://dx.doi.org/10.3390/cancers12092497

Ejemplares similares

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Burnout of health care providers during the COVID-19 pandemic: Focus on Medical Oncologists
por: Vici, Patrizia, et al.
Publicado: (2021)

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
por: Vici, Patrizia, et al.
Publicado: (2020)

Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting
por: Grassadonia, Antonino, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience
por: Barba, Maddalena, et al.
Publicado: (2021)

The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer
por: Mazzotta, Marco, et al.
Publicado: (2019)

Cancer patients and coronavirus disease 2019: evidence in context
por: Barba, Maddalena, et al.
Publicado: (2020)

Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?
por: Mazzotta, Marco, et al.
Publicado: (2021)

Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
por: Krasniqi, E., et al.
Publicado: (2019)

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial
por: Pizzuti, Laura, et al.
Publicado: (2020)

Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting
por: Di Benedetto, Anna, et al.
Publicado: (2019)

Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report
por: Barchiesi, Giacomo, et al.
Publicado: (2019)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study
por: Krasniqi, E., et al.
Publicado: (2021)

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial
por: Moscetti, Luca, et al.
Publicado: (2017)

Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey
por: Natoli, Clara, et al.
Publicado: (2014)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting
por: Mandoj, Chiara, et al.
Publicado: (2018)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study
por: Bon, Giulia, et al.
Publicado: (2023)

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
por: Pizzuti, Laura, et al.
Publicado: (2017)

Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting
por: Pizzuti, Laura, et al.
Publicado: (2017)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
por: Vici, Patrizia, et al.
Publicado: (2017)

A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression
por: Peri, Marta, et al.
Publicado: (2019)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
por: Roberto, Michela, et al.
Publicado: (2021)

PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
por: Pizzuti, Laura, et al.
Publicado: (2021)

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
por: Gamucci, Teresa, et al.
Publicado: (2018)

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nmpb8d0qfkb1mbm3ahfoapdi7g